This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

LipoScience Research Sheds Light On Novel Markers Via Nuclear Magnetic Resonance (NMR) Spectroscopy

RALEIGH, N.C., July 31, 2013 /PRNewswire/ -- Researchers from LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized NMR diagnostics to advance the quality of patient care in cardiovascular, metabolic and other diseases, are presenting two posters today that highlight the utility of the company's proprietary nuclear magnetic resonance (NMR) technology in measuring novel markers of systemic inflammation, as well as in diagnosing diabetes through measurement of blood glucose. The posters, which will be presented during the Technology/Design Development session at the American Association of Clinical Chemistry (AACC) annual meeting in Houston, Tex., will be on display today from 9:30 a.m. to 5:00 p.m.

GlycA and GlycB: Novel Markers of Systemic Inflammation

In one poster (#B-255), James Otvos and colleagues at LipoScience will present data on two novel markers of systemic inflammation, GlycA and GlycB that were derived from stored serum NMR spectra. Data collected at baseline from 5,680 participants in the Multi-Ethnic Study of Atherosclerosis (MESA) showed that GlycA and GlycB levels were associated with C-reactive protein (CRP, r~0.5-0.6) and fibrinogen, two acute-phase proteins that are commonly used to assess and monitor both acute and chronic inflammation. GlycA was also associated, independent of traditional risk factors, with future (6-year follow-up) coronary heart disease (CHD) events as well as with diabetes, all-cause death, and cancer.

"These data suggest that measurement of GlycA and GlycB via NMR spectroscopy can provide an assessment of inflammation status that is similar or complementary to existing inflammatory biomarkers, thereby aiding in risk assessment for inflammation-mediated cardiovascular disease," stated Dr. Otvos, who is Chief Scientific Officer at LipoScience. "Moreover, these novel markers of inflammation can be detected from NMR LipoProfile test spectra, which can further illuminate a patient's cardiovascular disease risk profile through quantification of lipoprotein particles in a blood sample."

High-Throughput Measurement of Serum Glucose in the Clinical Laboratory by NMR

In the second poster (#B-245), Dr. Thomas O'Connell and colleagues will demonstrate how a blood glucose assay, developed using NMR technology for LipoScience's Vantera ® Clinical Analyzer, can enable high-throughput measurement of glucose to aid in the diagnosis of diabetes and pre-diabetes.    When comparing glucose measurements made by NMR to those made by a standard chemistry assay, the investigators reported an excellent correlation between methods.

"While the fully automated Vantera Clinical Analyzer is currently used for measurement of lipoprotein particle concentrations, the information-rich nature of the NMR spectrum enables other clinically valuable metabolites such as glucose to be measured in the same spectrum," explained Dr. O'Connell. "Our results highlight the suitability of NMR for high-throughput automated quantification of glucose, which may facilitate diagnosis of diabetes and pre-diabetes."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs